NCT00142870

Brief Summary

A definable and significant withdrawal syndrome occurs upon cessation of chronic, heavy marijuana use. Bupropion (Zyban) is a medication currently used to treat withdrawal symptoms associated with tobacco use. The purpose of this study is to determine if bupropion will help individuals stop using marijuana.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Mar 2005

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2005

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

September 1, 2005

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 2, 2005

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2006

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2006

Completed
Last Updated

January 12, 2017

Status Verified

October 1, 2016

Enrollment Period

1.2 years

First QC Date

September 1, 2005

Last Update Submit

January 11, 2017

Conditions

Marijuana AbuseSubstance-Related Disorders

Keywords

marijuanatreatment

Outcome Measures

Primary Outcomes (1)

  • Withdrawal severity

    on a daily basis for 14 days

Study Arms (1)

A

PLACEBO COMPARATOR
Drug: Bupropion

Interventions

BupropionDRUG

150 mg, twice a day

Also known as: Zyban
A

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Current marijuana use and dependence
  • Marijuana use of at least 5 times in the past 7 days or more than 25 times per month for the 3 years prior to enrollment
  • Unsuccessful in a previous attempt to quit marijuana

You may not qualify if:

  • Axis I disorder
  • Any drug abuse or dependence other than marijuana
  • Currently taking antipsychotic or antidepressant medication
  • Heavy alcohol drinker (more than 20 drinks per week)
  • Current nicotine dependence
  • History of a seizure disorder
  • Current or prior eating disorder (e.g., bulimia or anorexia nervosa)
  • Heavy caffeine use (more than 300 mg per day)
  • Life threatening or unstable medical illness
  • Pregnant

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

McLean Hospital, Dept. of Psychiatry

Belmont, Massachusetts, 02478 9106, United States

Location

Related Publications (1)

  • Penetar DM, Looby AR, Ryan ET, Maywalt MA, Lukas SE. Bupropion reduces some of the symptoms of marihuana withdrawal in chronic marihuana users: a pilot study. Subst Abuse. 2012;6:63-71. doi: 10.4137/SART.S9706. Epub 2012 Jun 25.

    PMID: 22879754RESULT

Related Links

MeSH Terms

Conditions

Marijuana AbuseSubstance-Related Disorders

Interventions

Bupropion

Condition Hierarchy (Ancestors)

Chemically-Induced DisordersMental Disorders

Intervention Hierarchy (Ancestors)

PropiophenonesKetonesOrganic Chemicals

Study Officials

  • David M Penetar

    Mclean Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
NIH

Study Record Dates

First Submitted

September 1, 2005

First Posted

September 2, 2005

Study Start

March 1, 2005

Primary Completion

May 1, 2006

Study Completion

May 1, 2006

Last Updated

January 12, 2017

Record last verified: 2016-10

Locations

US(1)